| The impaired NK cell cytolytic function in viremic HIV‐1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44) A De Maria, M Fogli, P Costa, G Murdaca, F Puppo, D Mavilio, A Moretta, ... European journal of immunology 33 (9), 2410-2418, 2003 | 377 | 2003 |
| Emerging role of vitamin D in autoimmune diseases: An update on evidence and therapeutic implications G Murdaca, A Tonacci, S Negrini, M Greco, M Borro, F Puppo, S Gangemi Autoimmunity reviews 18 (9), 102350, 2019 | 267 | 2019 |
| Endothelial dysfunction in rheumatic autoimmune diseases G Murdaca, BM Colombo, P Cagnati, R Gulli, F Spanò, F Puppo Atherosclerosis 224 (2), 309-317, 2012 | 221 | 2012 |
| Vδ1 T lymphocytes producing IFN-γ and IL-17 are expanded in HIV-1–infected patients and respond to Candida albicans D Fenoglio, A Poggi, S Catellani, F Battaglia, A Ferrera, M Setti, ... Blood, The Journal of the American Society of Hematology 113 (26), 6611-6618, 2009 | 213 | 2009 |
| Infection risk associated with anti-TNF-α agents: a review G Murdaca, F Spanò, M Contatore, A Guastalla, E Penza, O Magnani, ... Expert opinion on drug safety 14 (4), 571-582, 2015 | 203 | 2015 |
| Serum interleukin‐17 levels are related to clinical severity in allergic rhinitis G Ciprandi, M De Amici, G Murdaca, D Fenoglio, F Ricciardolo, ... Allergy 64 (9), 1375-1378, 2009 | 196 | 2009 |
| Sjögren’s syndrome: a systemic autoimmune disease S Negrini, G Emmi, M Greco, M Borro, F Sardanelli, G Murdaca, F Indiveri, ... Clinical and experimental medicine 22 (1), 9-25, 2022 | 162 | 2022 |
| The antiphospholipid syndrome: from pathophysiology to treatment S Negrini, F Pappalardo, G Murdaca, F Indiveri, F Puppo Clinical and Experimental Medicine 17, 257-267, 2017 | 152 | 2017 |
| Current views on diagnostic approach and treatment of lymphedema G Murdaca, P Cagnati, R Gulli, F Spanò, F Puppo, C Campisi, F Boccardo The American journal of medicine 125 (2), 134-140, 2012 | 151 | 2012 |
| The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases G Murdaca, BM Colombo, F Puppo Internal and emergency medicine 6, 487-495, 2011 | 150 | 2011 |
| Migration of Vδ1 and Vδ2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1–infected patients: competition by HIV-1 Tat A Poggi, R Carosio, D Fenoglio, S Brenci, G Murdaca, M Setti, F Indiveri, ... Blood 103 (6), 2205-2213, 2004 | 146 | 2004 |
| Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV‐1‐infected patients M Fogli, P Costa, G Murdaca, M Setti, MC Mingari, L Moretta, A Moretta, ... European journal of immunology 34 (8), 2313-2321, 2004 | 145 | 2004 |
| COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series C Ferri, D Giuggioli, V Raimondo, M L’andolina, A Tavoni, R Cecchetti, ... Clinical rheumatology 39, 3195-3204, 2020 | 134 | 2020 |
| IL-33/IL-31 axis in immune-mediated and allergic diseases G Murdaca, M Greco, A Tonacci, S Negrini, M Borro, F Puppo, S Gangemi International journal of molecular sciences 20 (23), 5856, 2019 | 126 | 2019 |
| TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis G Murdaca, R Gulli, F Spano, F Lantieri, M Burlando, A Parodi, P Mandich, ... Journal of Investigative Dermatology 134 (10), 2503-2509, 2014 | 117 | 2014 |
| Apoptosis in the homeostasis of the immune system and in human immune mediated diseases R Paganelli, A Giovannetti, M Pierdominici, AD Iorio, R Cianci, G Murdaca, ... Current Pharmaceutical Design 14 (3), 253-268, 2008 | 117 | 2008 |
| Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy G Filaci, M Cutolo, M Scudeletti, C Castagneto, L Derchi, R Gianrossi, ... Rheumatology 38 (10), 992-996, 1999 | 117 | 1999 |
| Anti-TNF-α inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events G Murdaca, BM Colombo, F Puppo International journal of immunopathology and pharmacology 22 (3), 557-565, 2009 | 114 | 2009 |
| Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? G Murdaca, F Spanò, M Contatore, A Guastalla, E Penza, O Magnani, ... Expert opinion on drug safety 15 (1), 43-52, 2016 | 105 | 2016 |
| Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity G Murdaca, A Orsi, F Spanò, F Puppo, P Durando, G Icardi, F Ansaldi Autoimmunity reviews 13 (2), 75-84, 2014 | 87 | 2014 |
